2008: RA Treatment: Cytokine Directed Biological Therapy
Search or Browse by Day

RA Treatment: Cytokine Directed Biological Therapy

Monday, October 27, 2008
968
Golimumab, a Human Anti-TNFα Μonoclonal Antibody, Injected Every 4 Weeks: Efficacy & Safety in RA Patients Previously Treated with Anti-TNFα Agents (GO-AFTER Study)
969
Haemostatic And Inflammatory Biomarkers In Patients With Active Rheumatoid Arthritis: Effects Of Tumor Necrosis Factor Alpha Blockade
970
Algorithm using Genome-wide SNP Analysis for Prediction of Responder and Non-responder, and Adverse Events of Infliximab- or Etanercept-treated RA Patients
971
Effectiveness of TNF Inhibitors (TNF-I) in Biologic Naïve and Switched RA Patients in a U.S. Cohort
972
Safety And Efficacy Of Combination Therapy Cyclosporina - Anti-TNF Alpha Agents In Patients With Rheumatoid Arthritis And Hepatitis C Chronic Infection
973
Quantiferon-TB Gold Blood Test in Rheumatoid Arthritis Patients Using TNF-alpha Antagonists
974
Clinical Outcomes in Patients After One or Multiple anti-TNF Therapies in Rheumatoid Arthritis
975
Health Related Quality of Life and Fatigue Benefits in Rheumatoid Arthritis Patients were Sustained Over 2 Years of Treatment with Certolizumab Pegol
976
Plasma Type I Interferon (IFN) Activity Predicts Response to TNF-Antagonist Therapy in Rheumatoid Arthritis (RA) Patients
977
Combination Therapy With Certolizumab Pegol Plus Methotrexate Improves Household Productivity and Daily Activities in Patients With Active Rheumatoid Arthritis
978
Certolizumab Pegol With Methotrexate Improves Performance at Work in Patients With Active Rheumatoid Arthritis
979
Patients with Rheumatoid Arthritis Achieve a Rapid Response when Treated with Certolizumab Pegol Irrespective of Background Treatment
980
Improvements in Physical Function and Pain Relief were Sustained in Rheumatoid Arthritis Patients Treated for 2 Years with Certolizumab Pegol
981
Combination Therapy with Certolizumab Pegol Plus Methotrexate Maintains Long-Term Efficacy in the Treatment of Rheumatoid Arthritis: A 2-Year Analysis
982
Inhibition of Progression of Structural Damage by Week 16 with Certolizumab Pegol: Results from the RAPID Trials
983
Golimumab, A New Human Anti-TNF-α Monoclonal Antibody, Administered Subcutaneously Every 4 Weeks In Methotrexate-Naïve Patients With Active Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, GO-BEFORE Study
984
Etanercept Versus Glucocorticosteroids Intra-articular (ia) Injections In Rheumatoid Arthritis (ra): A Randomized Double Blind Study With Results At Weeks 4 And 24
985
The Comparison of Efficacy and Safety between Etanercept (ETN) Plus Methotrexate (MTX) Combination Therapy and ETN Monotherapy in MTX-refractory Japanese Patients with Rheumatoid Arthritis: 52-week Clinical Results from The JESMR Study
986
Better Disease Activity States are Achieved With Etanercept Treatment in Patients With Moderate Rheumatoid Arthritis vs Severe Rheumatoid Arthritis
987
Lipid and Inflammatory Biomarker Profiles in Patients Receiving Tocilizumab for Rheumatoid Arthritis: Analysis of Five Phase 3 Clinical Trials
988
Tociluzumab (TCZ) Monotherapy Improves Rheumatoid Arthritis (RA) Outcomes Regardless of Disease Duration
989
Tocilizumab Treatment Results in Rapid Improvements in the Signs and Symptoms of Moderate-to-Severe Rheumatoid Arthritis in Four Patient Populations with Different Prior Therapy Exposure
990
Patients Achieve Significant Improvement in Rheumatoid Arthritis (RA) Outcomes with Tociluzumab (TCZ) Regardless of Prior Inadequate Response (IR) to TNF Antagonists
991
Tociluzumab (TCZ) Improves Quality of Life (QOL) in Patients with Rheumatoid Arthritis (RA) who had Inadequate Response (IR) to TNF Antagonists
992
The Anti-IL6 Receptor Inhibitor Tocilizumab (TCZ) Combined with Methotrexate (MTX) Induces a Rapid and Sustained Decrease of Bone and Cartilage Degradation in Patients with Rheumatoid Arthritis (RA)
993
Low Immunogenic Potential of Tocilizumab in Patients with Rheumatoid Arthritis: Analysis of Four Phase 3 Clinical Trials
994
Results of a Phase 2 Randomized, Double-Blind Study of AMG 108 (a Fully Human Monoclonal Antibody to IL-1R type I) in Patients with Rheumatoid Arthritis
995
Initial Combination Therapy with Adalimumab and Methotrexate Leads to Better Long-Term Inhibition of Radiographic Progression in Early RA: 5-Year Results of the PREMIER Trial
996
Initial Combination Therapy with Adalimumab and Methotrexate Sustains Clinical Remission and Response for Early RA Patients Treated Through Year 5
997
Adalimumab Inhibited Radiographic Progression More Effectively Than Methotrexate in Early RA Patients Who Had Achieved a Normal C-Reactive Protein Concentration
998
Adalimumab Clinical Trial Results in Patients with Rheumatoid Arthritis (RA) Provide Proposed Improvement Categories for a Routine Assessment of Patient Index Data (RAPID3)
999
Adalimumab Dose Escalation Improves Clinical Responses In Patients With Rheumatoid Arthritis (RA)
1000
Adding Infliximab to Triple DMARD plus Prednisolone Therapy Reduces Absence from Work in Patients with Early Active Rheumatoid Arthritis. Results from a Double-blind Placebo-controlled Study (NEO-RACo)
1001
Denosumab Prevents Metacarpal Shaft Cortical Bone Loss in Patients with Erosive Rheumatoid Arthritis
1002
The Clinical Efficacy Of Repeated Courses Of Rituximab And The Kinetics Of B Cell Depletion In Primary Rituximab Non-responders
1003
In Patients with Early RA who Fail Initial MTX, the Addition of Anti-TNF Yields Better ACR and Eular Responses than the Addition of Conventional DMARDs: 1-Year Results of the SWEFOT Clinical Trial
1004
Treatment with PEGylated TNF-related Apoptosis-inducing Ligand (TRAIL) Induces Apoptosis of Human Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS) and Suppresses Arthritis in Murine Collagen-induced Arthritis
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>